Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : Brazil and Argentina tapped to make mRNA vaccines in Latin America

09/21/2021 | 05:57pm EDT

BRASILIA, Sept 21 (Reuters) - The Pan American Health Organization (PAHO) has selected two biomedical centers in Argentina and Brazil as regional hubs to develop and produce mRNA-based vaccines to fight COVID-19 in Latin America, the regional health agency said on Tuesday.

The idea is to tap existing manufacturing capacities to help transfer vaccine technology developed by Moderna in the United States to a region badly hit by the coronavirus and still without access to enough vaccines.

The Bio-Manguinhos Institute of Technology on Immunobiologicals at Fiocruz, Brazil's premier biomedical lab, was picked for its history of vaccine manufacturing, and has already made "promising advances" developing mRNA vaccine technology, PAHO said.

Sinergium Biotech, a private sector biopharmaceutical company, was selected as the center in Argentina and will partner with pharmaceutical lab mAbxience of the same group to develop and manufacture active vaccine ingredients.

The Americas branch of the World Health Organization said vaccine manufacture should benefit the entire region, with distribution funded by PAHO's Revolving Fund.

A similar effort in Africa to develop COVID-19 vaccine production replicating Moderna's shot has been slowed by talks with the U.S. company, a WHO official told Reuters last week.

Moderna said in October it would not enforce patents related to its shot during the pandemic, raising hopes that other companies might be able to copy its vaccine and help boost global production.

In practice, though, it is hard to replicate a vaccine without the information on how it is made, and the WHO-backed tech transfer hub in South Africa has so far not reached a deal with the company.

The Americas region has borne the brunt of COVID-19 infections to date, with 87.6 million cases recorded and over 2.16 million lives lost. Yet vaccine distribution continues to be unequal, PAHO has said, with few countries in the region reaching the year-end 40% vaccine target set by the WHO. (Reporting by Anthony Boadle Editing by Marguerita Choy)


© Reuters 2021
All news about MODERNA, INC.
04:01pMODERNA : U.S. has administered nearly 414 mln doses of COVID-19 vaccines
RE
03:32pMODERNA : U.S. has administered nearly 414 mln doses of COVID-19 vaccines
RE
03:14pMODERNA : U.S. CDC Says Administered 413,645,478 Doses Of Covid-19 Vaccine As Of Oct 24
RE
06:06aAP NEWS IN BRIEF AT 6 : 04 a.m. EDT
AQ
10/23MODERNA : U.S. CDC Says Delivered 503,521,625 Doses Of Covid-19 Vaccine As Of Oct 23
RE
10/22MODERNA : Canada considers what to do with millions of unused COVID-19 vaccine doses
AQ
10/22MODERNA : U.S. administers nearly 412 mln doses of COVID-19 vaccines - CDC
RE
10/22MODERNA : COVID SCIENCE-COVID-19 vaccines not linked to pregnancy loss; mixing vaccines ma..
RE
10/22CVS HEALTH : Pharmacies Start Offering Moderna COVID-19 Booster Shots
MT
10/22EXPLAINER : Is it time to get a COVID-19 booster? Which one?
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 374 M - -
Net income 2021 12 558 M - -
Net cash 2021 13 559 M - -
P/E ratio 2021 10,9x
Yield 2021 -
Capitalization 132 B 132 B -
EV / Sales 2021 5,80x
EV / Sales 2022 5,10x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 326,54 $
Average target price 295,79 $
Spread / Average Target -9,42%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455
ALNYLAM PHARMACEUTICALS, INC.52.81%23 604